Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01841905
Previous Study | Return to List | Next Study

Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease (Scope)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01841905
Recruitment Status : Unknown
Verified January 2016 by Rhode Island Hospital.
Recruitment status was:  Active, not recruiting
First Posted : April 29, 2013
Last Update Posted : January 20, 2016
Sponsor:
Collaborators:
Pfizer
Heidelberg Engineering, Inc.
Neurotrack
Optovue
Avid Pharmaceuticals
Information provided by (Responsible Party):
Rhode Island Hospital

Tracking Information
First Submitted Date April 24, 2013
First Posted Date April 29, 2013
Last Update Posted Date January 20, 2016
Study Start Date July 2013
Estimated Primary Completion Date December 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 26, 2013)
Groton Maze Learning Test [ Time Frame: 18 Months ]
Total number of correct moves over 5 trials on the Groton Maze Learning Test at 3 hours
Original Primary Outcome Measures Same as current
Change History
Current Secondary Outcome Measures
 (submitted: May 20, 2014)
  • Groton Maze Learning Test [ Time Frame: 18 Months ]
    Mean number of correct moves per second on the Groton Maze Learning Test at 3 hours
  • CogState One-Back Learning (OBK) Task [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • 12-Item International Shopping List Test - Immediate and Delayed Recall (CogState) [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Rentz Face-Name Association Test [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Stark Pattern Separation Test [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Minnesota Cognitive Acuity Scale (MCAS) [ Time Frame: Pre-baseline ]
    Screening acuity.
  • Saliva Sample for DNA Analyses (ApoE and BDNF genotyping) [ Time Frame: Baseline ]
    Mutation status.
  • Non-invasive imaging of macula, retinal function and visual fields [ Time Frame: 18 Months ]
    Change over time.
  • CogState Once-Card learning (OCL) Task [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Amyloid and Alzheimer's Psycho-educational Session [ Time Frame: 9 and 18 month study visits ]
    An informational exercise to provide further information about amyloid PET imaging and to determine the impact of this disclosure of study participants.
  • Tokyo Subway Navigation [ Time Frame: 9 month follow-up visit ]
    A functional activity of daily living where study participants are given pre-determined destinations / conditions and asked to map the route. Main outcome measure for this assessment is time taken to solve the problem.
  • MAC-Q [ Time Frame: Pre-screen, Baseline, 9 & 18 month follow-up ]
    A six-item scale measuring age-related memory decline. An overall index of cognitive decline is calculated by summing scores for all six items with double weighting for item #6. Higher scores indicate greater decline in memory.
Original Secondary Outcome Measures
 (submitted: April 26, 2013)
  • Groton Maze Learning Test [ Time Frame: 18 Months ]
    Mean number of correct moves per second on the Groton Maze Learning Test at 3 hours
  • CogState One-Back Learning (OBK) Task [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • 12-Item International Shopping List Test - Immediate and Delayed Recall (CogState) [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Paced Auditory Serial Addition Test (with Diad Scoring) [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Rentz Face-Name Association Test [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Stark Pattern Separation Test [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Minnesota Cognitive Acuity Scale (MCAS) [ Time Frame: Pre-baseline ]
    Screening acuity.
  • Single-lead surface EEG measurement of power band spectra [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Buccal swab for DNA Analyses (ApoE genotyping) [ Time Frame: Baseline ]
    Mutation status.
  • Non-invasive imaging of macula, retinal function and visual fields [ Time Frame: 18 Months ]
    Change over time.
  • CogState Once-Card learning (OCL) Task [ Time Frame: 18 Months ]
    Overall performance across study visits.
  • Buccal swab for DNA analysis (BDNF genotyping) [ Time Frame: Baseline ]
    Mutation status.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
Official Title Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease
Brief Summary The investigators are conducting a study to try to improve our ability to identify older adults who are at high-risk for progression to Alzheimer's disease, several years before they have symptoms that might reduce their quality of life. The investigators believe they can increase the sensitivity of tests of memory and problem solving, by using a very small dose of a medication (scopolamine) that reduces the activity of the principal chemical system in the brain that is changing in the earliest stages of Alzheimer's disease. By pairing this "micro-dose" drug challenge (that is administered with a tiny needle placed just under the surface of the skin on the forearm), with our tests of memory and thinking, it is believed that the investigators can create a "stress test" that is very similar in concept to the use of the exercise treadmill to make the results of a heart EKG more sensitive to detect early disease, as a cardiac stress test for heart disease. The investigators want to create a similar stress test for Alzheimer's disease (AD).
Detailed Description

We will take pictures of subjects' brains using PET imaging, in healthy older adults (ages 55 to 80 years) who have both a family history of AD, and who have concerns about changes in their memory (but no clinical symptoms of AD), to see how much of a protein - that is related to AD -is in their brains. When all subjects come to the hospital for PET imaging, we will review the entire study plan with them, the risks and benefits of participation, and we will obtain written informed consent at that time. Our goal is to compare performance on our new stress test to these PET imaging results. Once the PET imaging is done, we will have each subject come to our clinical research unit for a day-long baseline visit. In the morning we will give the tests of memory and thinking, and then we will administer the injection of scopolamine at a very low dose. We will then continue to examine the subjects, and to give the memory and thinking tests at 1, 3, 5, 7, and 8 hours post-dosing. Once they have fully-recovered from all effects of the medication, they will be allowed to go home that day. We will then see all subjects again, for much shorter visits to complete the cognitive tests, at both 9 and 18 months after their initial study visit. We will follow all subjects for 18 months to see which of them show very mild but measurable changes on the memory and thinking tests, as we predict that these will be the same persons who also had stronger results on our stress test at the first study visit.

At all three study visits to our clinical research unit, we will obtain measurements using an imaging device that uses infrared and blue light to take picture of the eye and retina. Our secondary goal in this study to search for evidence of the same protein, in the retina, that builds up and is seen with PET imaging of the brain in persons who are at high risk for AD. Finally, we are also collecting a small sample of saliva, at the first visit to our unit, in order to see which subjects have a genetic risk for the disease, as this genetic risk may affect how we interpret the results of our new "cognitive stress test".

In this study, a small dose of an already approved medication (used to treat seasickness) will be used to temporarily, and safely, mimic signs of very early disease during just the first day of testing. This is a methodological study to determine if tests that measure how you think can predict the risk of dementia as we age.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Individuals between the ages of 55 and 80 years old, and who have two risk factors for AD (subjective memory complaints as ascertained on a standardized questionnaire and a positive family history for the disease).
Condition Alzheimer's Disease
Intervention Other: Observational Study
Observational Study
Study Groups/Cohorts Observational Study
Pre-Symptomatic Alzheimers' Disease
Intervention: Other: Observational Study
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: April 26, 2013)
60
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 2016
Estimated Primary Completion Date December 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Individuals between the ages of 55 and 80 years old (inclusive).
  • MMSE total score > 27
  • Two risk factors for AD:
  • Subjective memory complaints.
  • A positive (suspected) first-degree family history for the disease.
  • Permitted medications stable for at least 1 month prior to screening.
  • Subjects may take stable doses of antidepressants lacking significant anticholinergic side effects (do not have a history of major depression within the past year).
  • Estrogen replacement therapy.
  • Adequate visual and auditory acuity to allow neuropsychological testing.
  • Good general health or without any clinically significant abnormalities .
  • Vitamin supplements (including Vitamin E) will be acceptable.
  • Subjects must be willing and able to provide written informed consent.

Exclusion Criteria:

  • History of major traumatic brain injury, other known neurologic disease or insult
  • Mini Mental State Examination (MMSE)total score < 27
  • Regular (daily) use of narcotics or antipsychotic medications
  • Poorly-controlled major depression or another Axis I psychiatric disorder as described in DSM-IV within the past year.
  • Psychotic features, agitation or behavioral problems, within the last 3 months.
  • History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).
  • History of schizophrenia (DSM IV criteria).
  • Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including:
  • History of systemic cancer within the past 5 years (non-metastatic skin cancers are acceptable).
  • History of myocardial infarction in the past year or unstable or severe cardiovascular disease including angina or Congestive Heart Failure (CHF) with symptoms at rest.
  • Clinically significant obstructive pulmonary disease or asthma.
  • Clinically significant and unstable gastrointestinal disorder within two years.
  • Insulin-requiring diabetes or uncontrolled diabetes mellitus.
  • Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100).
  • History of clinically significant liver disease, coagulopathy, or vitamin K deficiency within the past 2 years.
  • History of symptoms of narrow-angle glaucoma.
  • Clinically significant obstructive uropathy
  • Use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4 weeks prior to screening.
  • Use of anti-Parkinsonian medications (e.g., Sinemet, amantadine, bromocriptine, pergolide and selegiline) within 2 months prior to screening.
  • Use of neuroleptics or narcotic analgesics within 4 weeks prior to screening.
  • Use of long-acting benzodiazepines or barbiturates within 4 weeks prior to screen.
  • Use of short-acting anxiolytics or sedative-hypnotics more frequently than 2 times per week within 4 weeks prior to screening (note: sedative agents should not be used within 72 hours of the baseline and follow-up visits.
  • Initiation or change in dose of an antidepressant lacking significant cholinergic side effects within the 4 weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable)
  • Use of systemic corticosteroids within 3 months prior to screening.
  • Medications with significant cholinergic or anticholinergic side effects within 4 weeks prior to screening.
  • Use of anti-convulsants within 2 months prior to screening.
  • Use of warfarin (Coumadin) within 4 weeks prior to screening.
  • Any prior use of any FDA approved medications for the treatment of Alzheimer's disease (e.g., tacrine, donepezil, or other newly approved medications).
  • Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening.
  • Subjects who, in the investigator's opinion, will not comply with study procedures.
  • Known hypersensitivity to F-18, tropicamide, and/or scopolamine or agents of this class of drugs.
Sex/Gender
Sexes Eligible for Study: All
Ages 55 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01841905
Other Study ID Numbers 900,421-477
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Rhode Island Hospital
Study Sponsor Rhode Island Hospital
Collaborators
  • Pfizer
  • Heidelberg Engineering, Inc.
  • Neurotrack
  • Optovue
  • Avid Pharmaceuticals
Investigators
Principal Investigator: Peter J. Snyder, Ph.D. Sr. Vice President & Chief Research Officer, Lifespan
PRS Account Rhode Island Hospital
Verification Date January 2016